Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: Case-control analysis within a UK primary care cohort

BMJ (Online)

Volumn 341, Issue 7772, 2010, Pages 545-

  Green, Jane ^a   Czanner, Gabriela ^a   Reeves, Gillian ^a   Watson, Joanna ^a   Wise, Lesley ^b   Beral, Valerie ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTACID AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; ETIDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; RISEDRONIC ACID;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG INDUCED CANCER; ESOPHAGUS CANCER; FEMALE; FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; SMOKING; STOMACH CANCER; TREATMENT DURATION; UNITED KINGDOM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DIPHOSPHONATES; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 77956542068     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c4444     Document Type: Article

References (27)

1. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213.
2. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl JMed 2009;360:89-90.
3. GPRD. The database. 2010.www.gprd.com/products/database.asp.
4. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-9.
5. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14.
6. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al, eds. Cancer incidence in five continents. Vol IX. IARC Press, 2007. (IARC Scientific publications number 160.)
7. National Institute for Health and Clinical Excellence. Technology appraisal guidance 160: alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osetoporotic fragility fractures in postmenopausal women (amended). NICE, 2010.
8. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis Int 2007;18:1023-31.
9. Hamilton SR, Aaltonen LA, eds. World Health Organization classification of tumours: pathology and genetics of tumours of the digestive system. IARC Press, 2000.
10. Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A, et al. Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst 2009;101:296-305.
11. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, for the Million Women Study Collaborators. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007;335:1134.
12. Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L. Gastric and esophagus events before and during treatment of osteoporosis. Calcif Tissue Int 2010:86;110-5.
13. Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:1789-90.
14. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:1789.
15. Nguyen DM, Schwartz J, Richardson P, El-Serag HB. Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Dig Dis Sci 2010; published online 16 April.
16. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010;304:657-63.
17. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, et al. Guidelines for the diagnosis and management of osteoporosis in post menopausal women and men from the age of 50 years in the UK. Maturitas 2009;62:105-8.
18. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428.
19. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:404-15.
20. Watson J, Wise L, Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 2007;63:843-9.
21. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD004523.
22. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD003376.
23. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD001155.
24. Ebeling PR. Clinical practice: osteoporosis in men. N Engl J Med 2008;358:1474-82.
25. Solomon DH, Rekedal L, Cadarette SM. Osteoporosis treatments and adverse events. Curr Opin Rheumatol 2009;21:363-8.
26. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010;102:799-802.
27. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. JAMA 1996;276:1404-8.